Grow Pharma UK Releases New Gelato Phenotype for Patient Prescriptions
Grow Pharma, a leading UK medical cannabis distributor, has added a new Gelato phenotype to its patient formulary, offering a balanced cannabinoid profile suitable for a wide range of conditions.
Grow Pharma, one of the UK's most established medical cannabis distributors, has added a new Gelato-derived phenotype to its patient formulary. The product has been developed for prescription use and features a balanced THC:CBD profile that specialists have indicated is well-suited to a broad range of patient needs.
Product Characteristics
The new Gelato phenotype has been selected and standardised for its stable cannabinoid profile and consistent terpene expression. Gelato-derived cultivars are characterised by their moderate THC content and notably balanced secondary cannabinoid and terpene profiles, which are associated with a more manageable effect profile for patients new to or sensitive to higher-THC products.
- THC content 18 to 20% (batch-standardised)
- CBD content 0.5 to 1%
- Dominant terpenes: myrcene, caryophyllene, limonene
- Cultivation: indoor, pharmaceutical-grade growing conditions
- Suitable for vaporisation with approved medical devices
Prescribing Applications
The balanced terpene and cannabinoid profile makes this product suitable for prescribing in a range of conditions, including chronic pain, anxiety, and sleep disorders. Its moderate THC concentration is often preferred for patients who need effective symptom management without the intensity associated with higher-potency products. Grow Pharma has confirmed that the product is available now through its distribution network.
Patients can view currently available balanced THC:CBD strains in our directory. To discuss whether this product is appropriate for your condition, speak with your prescribing specialist or find a new clinic through our clinic finder. Our prescription guide outlines how to get started if you are new to the UK medical cannabis system.
